Pergolide
As of the edition of 20 October 2026, Pergolide is a small molecule: withdrawn from the market in 2007; acts on DRD1, DRD2 and DRD3 and 2 more; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Withdrawn from market, 2007
- Kind
- Small molecule
- Brand name
- Permax
- First approved
- 30 December 1988 (US)
- Approvals on record
- 3 in 1 region
- Holder of the most recent approval
- Bausch Health
- Withdrawn from market
- 1 January 2007 (in some regions)
- Registered trials
- 9, 1 stopped early
- Disease areas
- Mental health; Chemically induced; Nervous system; Inherited and neonatal
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
3 company-target rows on route B and 3 company-target rows on route A because of this drug.
Companies on route B for this drug
In the product3 company-target rows are on route B because of Pergolide.
See the 3 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Companies on route A for this drug
In the product3 company-target rows are on route A because of Pergolide.
See the 3 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 5 | 2 | 0 | 0 |
| Phase 2 | 2 | 2 | 0 | 0 |
| Phase 3 | 1 | 1 | 0 | 0 |
| Phase 4 | 1 | 0 | 0 | 1 |
| All trials | 9 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Eli Lilly | Earlier holder | 1988 to now |
| Bausch Health | Acquired holder and Lead sponsor of trials | 2005 to now |